FAQ

mavoglurant

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
02420132017

Related topics

Related topics

2 relations

Narrower (1)

AFQ056

Broader (1)

Indoles

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
mavoglurant
Indoles
AFQ056

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study.
INTRODUCTION To determine if mavoglurant (modified release) as an augmentation therapy to selective serotonin reuptake inhibitors… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.
Fragile X syndrome (FXS), the most common cause of inherited intellectual disability and autistic spectrum disorder, is typically… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2016
2016
Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
Long-term use of levodopa (L-dopa) in patients with Parkinson's disease is associated with development of dyskinesia. This study… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?
2016
2016
Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies.
BACKGROUND Two phase 2 randomized, double-blind studies were designed to evaluate efficacy and safety of immediate-release (study… (More)
  • figure 1
  • table 1
Is this relevant?
2015
2015
Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension…
A phase II randomized, placebo-controlled, double-blind study and subsequent open-label extension study evaluated the efficacy… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2015
2015
Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics
Mavoglurant (MVG) is an antagonist at the metabotropic glutamate receptor-5 currently under clinical development at Novartis… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2015
2015
A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease.
BACKGROUND This study investigated the hypothesis that AFQ056 (mavoglurant), a selective metabotropic glutamate receptor 5… (More)
  • figure 1
  • figure 2
Is this relevant?
Review
2014
Review
2014
Mavoglurant as a treatment for Parkinson's disease.
INTRODUCTION A major unresolved issue in the Parkinson's disease (PD) treatment is the development of l-DOPA-induced dyskinesias… (More)
Is this relevant?
2013
2013
Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects.
The disposition and biotransformation of (14)C-radiolabeled mavoglurant were investigated in four healthy male subjects after a… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2013
2013
Validation of an LC-MS/MS method for the quantitative determination of mavoglurant (AFQ056) in human plasma.
A simple, sensitive, and selective liquid chromatography/tandem mass spectrometry method was validated for the identification and… (More)
Is this relevant?